Skip to main content

Table 2 Comparison of median differences between Virgan use and no Virgan use

From: Efficacy and safety of topical ganciclovir in the management of cytomegalovirus (CMV)-related anterior uveitis

Virgan on vs Virgan off: Median IQR p value
No. of episodes of uveitis recurrence per person year −0.88 [−5.49–0.30] 0.029
Days-to-quiescence per episode of uveitis −1.25 [−8.75–37.29] 0.610
Days-to-recurrence per episode of uveitis −143.75 [−422.5–144.75] 0.285